Timothy A. Graubert
Affiliations: | Biology & Biomedical Sciences (Computational Biology) | Washington University, Saint Louis, St. Louis, MO |
Area:
Genetics, Bioinformatics, OncologyGoogle:
"Timothy Graubert"Parents
Sign in to add mentor| Timothy J. Ley | post-doc | Washington University School of Medicine (Cell Biology Tree) |
Children
Sign in to add trainee| Patrick Cahan | grad student | 2009 | Washington University |
| Theresa Okeyo-Owuor | grad student | 2013 | Washington University |
| Megan R. Janke | grad student | 2014 | Washington University |
| Elise P. Lu | grad student | 2015 | Washington University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wander SA, Hasserjian RP, Oduro K, et al. (2022) Combined Targeted Therapy for -Mutant, Treatment-Related Acute Myeloid Leukemia. Jco Precision Oncology. 1: 1-7 |
| Wadugu BA, Nonavinkere Srivatsan S, Heard A, et al. (2021) U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. The Journal of Clinical Investigation |
| Malcovati L, Stevenson K, Papaemmanuil E, et al. (2020) SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood |
| Hasserjian RP, Steensma DP, Graubert TA, et al. (2020) Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia. Blood |
| Narayan R, Blonquist TM, Emadi A, et al. (2019) A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer |
| Brunner AM, Blonquist TM, DeAngelo DJ, et al. (2019) Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet. Haematology |
| van Galen P, Hovestadt V, Wadsworth Ii MH, et al. (2019) Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell |
| Haase D, Stevenson KE, Neuberg D, et al. (2019) TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia |
| Brunner AM, Neuberg DS, Wander SA, et al. (2018) Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer |
| Christopher MJ, Petti AA, Rettig MP, et al. (2018) Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. The New England Journal of Medicine |